Hepatitis B Treatment (cont.)
IN THIS ARTICLE
New nucleoside/nucleotide analogues are being developed to try to improve outcomes or limit side effects or resistance in hepatitis B. One example is emtricitabine (Emtriva), which is already approved for use in HIV. Other examples include clevudine (L-FMAU), pradefovir, alamifovir, valtorcitabine, and medications that are currently identified only with drug numbers such as ANA380 (LB80380), ANA-975, and others.
Although currently available vaccines against hepatitis B are not effective in patients who already have chronic hepatitis B, new vaccines are being developed that may one day help stimulate the body's immune system in combination with medical treatment.
Combination therapies using two nucleoside/nucleotide analogues or analogues plus pegylated interferon have not shown superiority to single-agent therapy.
Must Read Articles Related to Hepatitis B Treatment